Precigen (PGEN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$85.7M

Revenue (quarter)

$55.0M

Revenue growth (year over year)

+6322.66%

Gross profit (trailing twelve months)

$77.7M

Gross margin

90.67%

Net income (trailing twelve months)

−$157.7M

Net income (quarter)

$20.1M

Net income growth (year over year)

+175.34%

Net margin

−183.98%

Return on equity

−9907.46%

EPS (trailing twelve months)

−$1.07

Book value per share

$0.12

P/E (trailing twelve months)

—

Price to book

64.29

Debt to assets

74.41%

Payout ratio

—

Dividend yield

—

Company profile

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

• Is Precigen (PGEN) profitable?

  No. Precigen reported a net loss of $157.7M over the trailing twelve months.

• How much revenue does Precigen (PGEN) make?

  Precigen generated $85.7M in revenue over the trailing twelve months, up 6322.66% year over year.

• How do I buy stock in Precigen (PGEN)?

  PGEN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.